TITLE

Once-Weekly Fluoxetine: A Viewpoint by Alexander Neumeister and W. Wolfgang Fleischhacker

AUTHOR(S)
Neumeister, A.; Fleischhacker, W.W.
PUB. DATE
December 2001
SOURCE
Drugs;Dec2001, Vol. 61 Issue 15, p2229
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Comments on the therapeutic efficacy of fluoxetine for the treatment of major depressive disorder. Administration of once-weekly fluoxetine; Adverse effects of the drug; Education on the relevance of medication in the treatment of depression.
ACCESSION #
5692973

 

Related Articles

  • Treatment of depression in chronic fatigue syndrome.  // American Family Physician;6/1/1996, Vol. 53 Issue 8, p2653 

    Reports on a study by J.H. Vercoulen, et al, published in `Lancet' which evaluated the effectiveness of fluoxetine in the treatment of depression linked with chronic fatigue syndrome. Indication of lack of beneficial effect of fluoxetine on chronic fatigue syndrome.

  • Analysis of curative effect of fluoxetine and escitalopram in the depression treatment based on clinical observation. Zhang Xiaoling; Han Yunping; Lian Yingdong // Pakistan Journal of Pharmaceutical Sciences;2018 Special Issue, Vol. 31, p1115 

    Depression is a common affective disorder or mood disorder, which seriously affects people's physical and mental health and the quality of life. This study compared efficacy of escitalopram and fluoxetine on depression patients, and analyzed the inflammatory factors, serum homocysteine (Hcy)...

  • Combination therapy more effectively induces remission of major depressive disorder.  // JAAPA: Journal of the American Academy of Physician Assistants (;Jun2010, Vol. 23 Issue 6, p53 

    The article reports on a study which found that combination therapy with mirtazapine and other antidepressant medications is more effective than just fluoxetine for achieving remission of major depression.

  • Don't feel bad. Laliberte, Richard // Men's Health;Mar94, Vol. 9 Issue 2, p74 

    Focuses on drugs which can lift depression. Prozac; Side effects; The neurotransmitter serotonin; Tricyclics; Monoamine oxidase inhibitors; Zoloft, Paxil, Wellbutrin; Details.

  • SEEKING THE WIZARDS OF PROZAC. Thompson, Tracy // Saturday Evening Post;Mar/Apr94, Vol. 266 Issue 2, p50 

    Discusses the role of the drug Prozac or fluoxetine in treating depression. Eli Lilly and Company as manufacturers; Sales in 1992; Lawsuits against Lilly claiming Prozac as cause of homicidal or suicidal impulses; Treatment of melancholia in ancient Greece; Author's manic depression; Ray...

  • Fluoxetine. Gram, Lars F. // New England Journal of Medicine;11/17/94, Vol. 331 Issue 20, p1354 

    Summarizes the published information about fluoxetine (Prozac). Pharmacodynamics; Pharmacokinetics; Clinical indications; Dose-effect studies and the treatment of depression; Comparison with imipramine; Methodologic problems in studies of depression; Tolerability and adverse effects; Other aspects.

  • Singing the Prozac blues. Brink, Susan // U.S. News & World Report;11/8/93, Vol. 115 Issue 18, p76 

    Focuses on the antidepressant Prozac and the drug's reputation which has gone through wild mood swings. Prozac was the first of a radically new class of antidepressants called selective serotonin-reuptake inhibitors (SSRI); The advantage over earlier classes called tricyclics; Underestimated or...

  • GETTING PAST PROZAC. Graves, Ginny // Harper's Bazaar;May2000, Issue 3462, p100 

    Investigates the use of prozac in treating depression among women and offers tips on when to stop using the drug.

  • New Statistical Proposals to Evaluate the Benefit/Risk Ratio of Long-Term Treatment of Depression: Application to a One-Year Double-Blind Study Comparing Medifoxamine with Fluoxetine. Lehert, P.; Poirier-Littre, M.F.; Pringuey, D.; Galinowski, A. // Clinical Drug Investigation;1998, Vol. 15 Issue 4, p285 

    The aim of this study was to determine the benefit/risk ratio of long-term treatment with medifoxamine, a non-tricyclic, non-monoamine oxidase inhibitor agent, and fluoxetine in patients with acute depressive episode and at high risk of relapse and/or recurrence. The study involved a 12-month...

  • Fluoxetine: A Review of its Use in Anxiety Disorders and Mixed Anxiety and Depression. Hurst, M.; Lamb, H.M. // CNS Drugs;2000, Vol. 14 Issue 1, p51 

    Fluoxetine is a selective serotonin (5-hydroxytryptamine; 5-HT) reuptake inhibitor (SSRI). Although its mechanism of action in anxiety disorders is unclear, it is thought to act by enhancing serotonergic neurotransmission and down-regulating central receptors. In comparison with other SSRIs,...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics